{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:04:00Z","timestamp":1791932640252,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103639"],"award-info":[{"award-number":["P20GM103639"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA225520"],"award-info":[{"award-number":["P30CA225520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011526","name":"National Ovarian Cancer Coalition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018096","name":"GOG Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001298","name":"Presbyterian Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ygyno.2025.10.021","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:05:51Z","timestamp":1762351551000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Feasibility IB trial of paclitaxel\/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary"],"prefix":"10.1016","volume":"203","author":[{"given":"C.","family":"Washington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra Kumar Dhar","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gunderson-Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neelakantan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cohoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Gatalica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: a review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.10.021_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051100","article-title":"Target therapies for uterine Carcinosarcomas: current evidence and future perspectives","volume":"18","author":"Vitale","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.021_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2015.08.014","article-title":"Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis","volume":"139","author":"Rauh-Hain","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101672","article-title":"Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma","volume":"35","author":"Toboni","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2025.10.021_bb0030","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.prp.2013.06.017","article-title":"TGFbeta-pathway is down-regulated in a uterine carcinosarcoma: a case study","volume":"209","author":"Semczuk","year":"2013","journal-title":"Pathol. Res. Pract."},{"issue":"16","key":"10.1016\/j.ygyno.2025.10.021_bb0035","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.18632\/oncotarget.3711","article-title":"Role of TGF-beta signaling in uterine carcinosarcoma","volume":"6","author":"Dwivedi","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ygyno.2025.10.021_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.15698\/cst2020.11.234","article-title":"Targeting the TGFbeta pathway in uterine carcinosarcoma","volume":"4","author":"Dwivedi","year":"2020","journal-title":"Cell Stress"},{"issue":"11","key":"10.1016\/j.ygyno.2025.10.021_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.ygyno.2025.10.021_bb0050","article-title":"Uterine carcinosarcoma: unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential","volume":"38","author":"Gopinatha Pillai","year":"2024","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0055","first-page":"996","article-title":"Mutational landscape implicates epithelial-mesenchymal transition gene TGF-beta2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma","volume":"12","author":"Shen","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ygyno.2025.10.021_bb0060","doi-asserted-by":"crossref","unstructured":"Wilhite, A.M., et al., Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma. J. Clin. Oncol. 39(15_suppl): p. 5582\u20135582.","DOI":"10.1200\/JCO.2021.39.15_suppl.5582"},{"key":"10.1016\/j.ygyno.2025.10.021_bb0065","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"7693","key":"10.1016\/j.ygyno.2025.10.021_bb0070","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ygyno.2025.10.021_bb0075","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.021_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2025.10.021_bb0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a Bif 312 unctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"536","key":"10.1016\/j.ygyno.2025.10.021_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10585-021-10077-z","article-title":"TGFbeta signaling networks in ovarian cancer progression and plasticity","volume":"38","author":"Kumari","year":"2021","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.021_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1535-7163.MCT-20-0891","article-title":"Exploiting canonical TGFbeta signaling in cancer treatment","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-014-0192-4","article-title":"Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer","volume":"33","author":"Rodon","year":"2015","journal-title":"Investig. New Drugs"},{"issue":"10","key":"10.1016\/j.ygyno.2025.10.021_bb0115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"79","author":"Sutton","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.10.021_bb0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study","volume":"25","author":"Homesley","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.10.021_bb0130","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and Ifosfamide in patients with Carcinosarcoma of the uterus or ovary: an NRG oncology trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygyno.2007.07.070","article-title":"A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus","volume":"107","author":"Wolfson","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.10.021_bb0140","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","article-title":"Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"28","author":"Powell","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.10.021_bb0145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ygyno.2025.10.021_bb0150","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-07-2938","article-title":"Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways","volume":"68","author":"Onder","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2025.10.021_bb0155","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2353\/ajpath.2009.081018","article-title":"Requirement of the Akt\/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug","volume":"174","author":"Saegusa","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.10.021_bb0160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.humpath.2012.05.013","article-title":"Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis","volume":"44","author":"Romero-Perez","year":"2013","journal-title":"Hum. Pathol."},{"issue":"6 Pt 2","key":"10.1016\/j.ygyno.2025.10.021_bb0165","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1083\/jcb.127.6.2021","article-title":"TGF-beta induced transdifferentiation of mammary 344 epithelial cells to mesenchymal cells: involvement of type I receptors","volume":"127","author":"Miettinen","year":"1994","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.10.021_bb0170","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1091\/mbc.e04-08-0658","article-title":"TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition","volume":"16","author":"Valcourt","year":"2005","journal-title":"Mol. Biol. Cell"},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0175","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","article-title":"TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer","volume":"123","author":"Bhola","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ygyno.2025.10.021_bb0180","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/or.2011.1151","article-title":"Expression of TGFss1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel\/carboplatin","volume":"25","author":"Komiyama","year":"2011","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ygyno.2025.10.021_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGFbeta-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.ygyno.2025.10.021_bb0190","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2025.10.021_bb0195","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance Durvalumab with or without Olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.10.021_bb0205","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/PAS.0000000000001434","article-title":"Mismatch repair deficiency in uterine Carcinosarcoma: a multi-institution retrospective review","volume":"44","author":"Jenkins","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.10.021_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2025.10.021_bb0220","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","article-title":"Bintrafusp alfa for recurrent or metastatic cervical cancer after platinum failure: a nonrandomized controlled trial","volume":"10","author":"Birrer","year":"2024","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:35:14Z","timestamp":1773095714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"alternative-id":["S0090825825010455"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility IB trial of paclitaxel\/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}